You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雅各臣科研製藥(02633.HK)將加大亞洲市場銷售
阿思達克 07-03 16:37

雅各臣科研製藥(02633.HK)首席商務官黃一偉在傳媒午宴上表示,公司除了發展香港本地市場外,未來希望繼續於亞洲最大化產品組合價值,包括大中華、南亞及北亞三個市場。在進入較大的東南亞市場,例如韓國、泰國及日本時會在當地尋找合作夥伴,市場較小的則會採取與分銷商合作。目前公司有93%的收入來自本地,7%來自其他亞洲地區,期望未來三年間,來自香港的收入佔比會下降至80至85%,其他亞洲地區的佔比則上升至15%。

公司已提交了61份非專利藥申請,當中14份已獲批准,預計今年將獲得25份以上的批准。今年來,參與了11項香港的招標項目。他預期,獲批的非專利藥將會在2020年第二季起迎來收成期。除此之外,公司亦會開發新產品的市場潛力,包括家用診斷產品、消費者保健及醫學營養產品等。

執行董事嚴振亮提到,除了研發非專利藥並自行生產外,公司會採用引進授權的方式引入新產品,此舉可令公司在獲得增長的同時,亦不會加重生產負擔,令成本獲得更好的控制。公司在引進授權時,會選擇毛利率達50%的藥品,強調只會做市場少有的藥品。

在品牌成藥方面,嚴氏指保濟丸在2019財年錄逾10%的銷售增長,但對此表現仍不感滿意,希望能在未來一個財年加強國內銷售。而在發展國內市場時,會與股東雲南白藥合作。至於旗下藥品每年都會跟隨通脹加價5至8%,加價時間則不定。(jc/a)

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account